Genelux

GNLX · NASDAQ

$2.50+$0.05 (+2.04%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $2.45

GNLX analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 7 analysts

Average $19.38 (+675.2% upside)

Low: $12.12
Now: $2.50
High: $32.55

Upgrades and downgrades

The latest rating actions, newest first

GNLX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Benchmark	Mar 20, 2026	Maintains	Speculative Buy	$23.00 → $20.00	59%
Lake Street	Oct 21, 2025	Initiates	Buy	$16.00	27%

The case for and against

Updated Feb 15, 2025

Bull case

Genelux Corp's stock displays a positive outlook due to the promising clinical efficacy of its lead product, Olvi-Vec, which has demonstrated a notable overall response rate of 54% and a median progression-free survival of 11 months in patients undergoing treatment. The company's projections suggest that successful trial results could boost the stock's potential upside significantly, with possibilities for improved metrics as trials progress, particularly in the treatment of difficult solid tumors like lung metastases. Additionally, the ability of Olvi-Vec to enhance PD-L1 expression presents opportunities to potentially overcome checkpoint inhibitor resistance, further strengthening the case for its use in aggressive cancers.

Bear case

Genelux Corp faces significant uncertainties regarding the efficacy and safety of its product candidates, with the potential for clinical trials to fail, which could markedly reduce the value of its assets. The company may struggle to capture meaningful market share even if its products receive approval, as acceptance from key stakeholders such as physicians and third-party payers remains uncertain. Additionally, financing requirements and potential delays or rejections in regulatory approval may further impede the valuation of Genelux's offerings and threaten its long-term financial stability.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.